David O'Malley, MD

David O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.

David O’Malley, MD, discusses the mechanism of action of ubamatamab as well as findings from a phase 1 trial evaluating the agent in patients with recurrent ovarian cancer.

David O’Malley, MD, discusses updated results from the KEYNOTE-158 trial of pembrolizumab in patients with advanced endometrial cancer.

David O'Malley, MD, looks at the preclinical signals of the novel MUC16 antibody ubamatamab, which showed promising results for patients with recurrent ovarian cancer.

David M. O’Malley, MD, discusses the management of adverse events across various regimens for cervical cancer treatment and provides insight on future directions for disease management.

Dr David M. O’Malley comments on emerging agents in the pipeline for the treatment of recurrent/metastatic cervical cancer and shares his approach to the sequencing of therapies.

David M. O’Malley, MD, shares insight on data presented at SITC 2021 on the use of a second-generation, Fc-enhanced anti-CTLA4 antibody, AGEN1181, in patients with advanced cervical cancer as well as other solid tumors.

Dr David M. O’Malley reviews ESMO 2021 updates evaluating the use of combination anti-PD-1 and anti-CTLA4 agents for recurrent and metastatic cervical cancer.

An expert gynecologic oncologist discusses the rationale for using PD-L1 inhibitors and CTLA4 inhibitors in gynecologic cancers.

David M. O’Malley, MD, provides insight on the evolution of cervical cancer and reviews current systemic treatment options for recurrent and advanced disease.

David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.

David O'Malley, MD, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.